UNSPSC 51271505: Chlorobutanol hemihydrate

This classification denotes an industrial aid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X4P6271OX. European Medicines Agency schedules Chlorobutanol hemihydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11812MIG. Chlorobutanol hemihydrate generally arises in the molecular formula 2C4H7CL3O.H2O. The term 'chlorobutanol hemihydrate' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule chlorobutanol hemihydrate under HS 29055910 and SITC 51229.

As of Q4 2014, CHLOROBUTANOL HEMIHYDRATE remains US FDA's Preferred Term for this commodity. Chlorobutanol hemihydrate bears US NLM identifiers UMLS ID C0725608 and NCI Concept Code C79995. SMILES: CC(C)(C(CL)(CL)CL)O.CC(C)(C(CL)(CL)CL)O.O.

UNSPSC 51271505 Chlorobutanol hemihydrate is a Commodity code representing a specific pharmaceutical ingredient used in formulated products. State and local governments procure chlorobutanol hemihydrate and related generic pharmaceuticals primarily through cooperative purchasing agreements that bundle multiple drug products and over-the-counter items for distribution across state agencies, local health departments, schools, and other public facilities. The issuing bodies are predominantly state purchasing offices administering multistate cooperative purchasing vehicles, supplemented by local health authorities and facility operators that draw on these contracts. Work under the code involves supplying manufacturers' products that meet FDA compliance, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) standards, with vendors required to maintain relationships with authorized pharmaceutical wholesalers and provide detailed product information including National Drug Codes, SKUs, and pricing in formats compatible with electronic data interchange systems.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products effective July 1, 2026, with responses due March 26, 2026. The solicitation covers participating state and local government facilities across Minnesota and Oregon, with awarded vendors required to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must demonstrate pricing competitiveness (weighted at 75 percent of evaluation), maintain comprehensive insurance including $5,000,000 commercial general liability, agree to a 3 percent administrative fee on purchases, and comply with performance penalties of $200 to $1,500 per violation for late reporting or onboarding delays. The contract term is two years for new responders with optional extensions at MMCAP's discretion, or amendments through June 30, 2028 for incumbent responders.